SuperworthRigel Pharmaceuticals EPS RIGL
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $16.05
- Latest quarter, Q2 FY26
- $0.88
- −73% on a year earlier
- Fiscal year 2025
- $18.64
- +1822% on the year before
Rigel Pharmaceuticals' earnings per share was $16.05 over the twelve months to Jun 30, 2026, up 197% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.88, down 73% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $18.64 | +1822% |
| FY2024 | $0.97 | n/a |
| FY2023 | −$1.47 | n/a |
| FY2022 | −$3.40 | n/a |
| FY2021 | −$1.10 | n/a |
| FY2020 | −$1.60 | n/a |
| FY2019 | −$4.00 | n/a |
| FY2018 | −$4.50 | n/a |
| FY2017 | −$6.10 | n/a |
| FY2016 | −$7.40 | n/a |
| FY2015 | −$5.90 | n/a |
| FY2014 | −$10.30 | n/a |
| FY2013 | −$10.10 | n/a |
| FY2012 | −$13.30 | n/a |
| FY2011 | −$13.80 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.88 | −73% | $16.05 | |
| Q1 FY26 | $0.44 | −30% | $18.45 | |
| Q4 FY25 | $13.27 | +1559% | $18.64 | |
| Q3 FY25 | $1.46 | +109% | $6.17 | |
| Q2 FY25 | $3.28 | n/a | $5.41 | |
| Q1 FY25 | $0.63 | n/a | $2.07 | |
| Q4 FY24 | $0.80 | +1900% | $0.97 | |
| Q3 FY24 | $0.70 | n/a | $0.21 | |
| Q2 FY24 | −$0.06 | n/a | −$0.82 | |
| Q1 FY24 | −$0.47 | n/a | −$1.14 | |
| Q4 FY23 | $0.04 | −60% | −$1.47 | |
| Q3 FY23 | −$0.33 | n/a | −$1.41 |
Against its peers
Companies in Drug Manufacturers - General nearest Rigel Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RIGLRigel Pharmaceuticals | $16.05 | +197% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| OMEROmeros | $1.52 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| Peer median | $1.08 |
Where Rigel Pharmaceuticals ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Rigel Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.